Eli Lilly's Foundayo Shows Stronger Weight Loss in Older Adults Than Overall Trial Average

The FDA-approved GLP-1 pill achieved 12.4% average body weight loss in the ATTAIN-1 trial but 13% in adults aged 65 and older—a clinically significant distinction. Older adults have historically struggled with injectable GLP-1s due to polypharmacy, swallowing difficulties, and care coordination. An unrestricted oral formulation addresses these barriers substantially, potentially unlocking GLP-1 uptake in long-term care and home health settings where obesity intersects densely with comorbidity.